LH Stock to Gain From Launch of HPV and STI Self-Collection Options

Labcorp Holdings, Inc. (LH) has announced the nationwide launch of an FDA-approved human papillomavirus (HPV) self-collection solution that can help women and their physicians assess the risk of developing cervical cancer. Additionally, the company will offer a vaginal swab self-collect option for sexually transmitted infection (STI) testing.Both solutions require a physician’s order and can be completed privately in a healthcare setting or at any one of Labcorp's 2,200 Patient Service Centers (PSCs) nation ...